Shanghai Allist Pharmaceuticals Co., Ltd is co-founded by Mr. Du Jinhao, a renowned entrepreneur, and Dr. Guo Jianhui, tenured scientist of The United States National Institutes of Health (NIH) in. Headquartered in Zhangjiang Hi-Tech Park since its founding in March 2004, Allist has built itself into an innovative pharmaceutical company, discovering, developing, manufacturing and commercializing innovative medicines. 

Under the development concept of “advancing long life with innovation of science and technology”, it is oriented by the unmet clinical demands in the global pharmaceutical market, with special focus on tumor treatment. Allist seeks to develop first-in-class and best-in-class medicines with uncompromised devotion to produce safe, effective, and inclusive innovative drugs with independent intellectual property rights.

After the A and A+ rounds of financing in 2019, Allist was formally listed on the Sci-Tech Innovation Board (STAR) market via the Shanghai Stock Exchange on December 2, 2020 (Stock code: 688578).


Located in the Medicine Valley in Zhangjiang Hi-Tech Park in Shanghai, Allist R&D Center boasts a total of 130 researchers and scientists. It now has a complete set of processes for the research and development of new drugs, including drug discovery, preclinical studies, clinical trial application, clinical trials, new drug approval, and post-approval research, etc.

Founded in 2019, Shanghai Allist Marketing Planning Co., Ltd. now has a marketing & sales service network that covers 31 provinces, municipalities, and autonomous regions across the country and a marketing & sales team of over 350 members.

As an innovative pharmaceutical industrialization base invested by Shanghai Allist Pharmaceuticals, Jiangsu Allist Pharmaceuticals Co.,LTD was founded in Sept 2009 with a  registered capital of 240 million RMB.

  • Established Shanghai Allist Pharmaceutical Technology Co., Ltd.

  • China NMPA approved the clinical trial of Allisartan Isoproxil

  • Expanded Allist Research & Development Center

    Allisartan Isoproxil clinical study listed among the 863 major disease research projects for modern medicine recognized by the Ministry of Science and Technology of China

  • Launched proton pump inhibitor

    (Lansoprazole enteric-coated pellet capsules)

  • Established Jiangsu Allist Biomedical Co., Ltd.

    “Study of the Year” as recognized by Medicine Valley in Zhangjiang Hi-Tech Park, Shanghai

    Received a special grant from Jiangsu Province for the commercialization of scientific and technological achievements

    Allisartan Isoproxil successfully recognized as a major national

  • China NMPA approved Allisartan Isoproxil as the first Class I anti-hypertension sartan drug available in the Chinese market

  • Allisartan Isoproxil patent rights transferred to Shenzhen Salubris Pharmaceuticals Co., Ltd.

    High and New Technology Enterprise (HNTE); passed reexamination in 2016

  • China NMPA approved the clinical trial of Furmonertinib

  • Completed the A/A+ rounds of financing

    Established Shanghai Allist Pharmaceuticals LLC after shareholding system reform completed

    Established Shanghai Allist Marketing Planning Co., Ltd.

    China NMPA granted Furmonertinib with priority review & approval procedures

    Ground-broke Headquarter R&D Base at Shanghai International Medical Park in Pudong New Area

  • Partnered with OCTIMET Oncology for joint treatment with Furmonertinib

    Listed on the SSE STAR market

    Top 100 China Medical Innovation in 2020

    Zhangjiang Venture 2020 Annual Outshanding Innovation Company

  • China NMPA approved Furmonertinib for the treatment of locally advanced or metastatic non-small cell lung cancer, Allist’s second national Class 1 innovative drug

    Jishi Cup Top 10 Pharmaceutical Innovation Companies in 2020 by Securities Times

    Top 10 Listed Biopharmaceutical Companies in 2020

    Member of China Pharmaceutical Innovation and Research Development Association

    Founding member of China Pharmaceutical Innovation 100 Union

    Emerging Medical Innovator in China 2021 by PHIIC

    Furmonertinib Added to 2021 China’s National Medical Insurance Catalog

    Top 100 China Medical Innovation in 2021

    Allist and ArriVent Biopharma, Inc. reached an overseas exclusive licensing deal for  Furmonertinib

    Allist signed a technology transfer assignment for Phosphoglycerate mutase 1 (PGAM1) Inhibitor KH3 with Fudan University

  • Jishi Cup Top 10 Innovation Drugs in 2021 by Securities Times

    Furmonertinib Approved for First-Line Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations.

    TOP 100 Shanghai Sheer Science and Technology Companies

    Furmonertinib Awarded as TOP 10 Domestic New Drug by the 14th Healthy China Forum

Science Advisory Broad

Science Advisory Broad (SAB) will provide scientific guidance in pipeline strategy, internal project pitching review, project management, external collaboration, asset license-in, clinical development, and team establishment to Allist Pharmaceuticals, leading Allist to a next level of innovation and development.